Acquisition of own shares in the framework of employees’ long-term incentive plans
BRUSSELS, Belgium, 5 May 2011 – 19:30 (CET) – regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 66.683 UCB shares on the Brussels stock exchange on the dates and at the prices indicated hereunder:
These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company’s share option plans of which the detail is given in UCB annual report.
UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, email@example.com
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, Michael.firstname.lastname@example.org
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.
Stay up-to-date on the latest news and information from UCB